Altered genome‑wide hydroxymethylation analysis for neoadjuvant chemoradiotherapy followed by surgery in esophageal cancer
- Xianjing Zhang
- Mingzhu Lu
- Jing Zhu
- Changsong Zhang
- Meihua Wang
Affiliations: The Second Clinical Department, Medical School of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Pathology, Changzhou Cancer Hospital, Soochow University, Changzhou, Jiangsu 213032, P.R. China, Department of Laboratory Medicine, Suzhou Science and Technology Town Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu 215153, P.R. China
- Published online on: November 24, 2022 https://doi.org/10.3892/etm.2022.11728
Copyright: © Zhang
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Esophageal cancer has high incidence rate in China. Neoadjuvant chemoradiotherapy (nCRT) has become the standard treatment for esophageal squamous cell carcinoma (ESCC). However, there are few reliable epigenetic parameters for patients with ESCC undergoing neoadjuvant therapy. Genomic extract from tumor tissue was amplified and sequenced using the Illumina HiSeq4000 to quantify genes associated methylation or hydromethylation in 12 patients with ESCC undergoing nCRT. The genome‑wide hydroxymethylation were analyzed by methylated and hydroxymethylated DNA immunoprecipitation sequencing by MACS2 software and UCSC RefSeq database. Abnormal DNA methylation was statistically different between nCRT‑well (showed a pathological complete response to nCRT) and nCRT‑poor (showed incomplete pathological response to nCRT) patients. Levels of ten‑eleven translocation 1, 2 and 3 mRNA and protein were higher in tumor tissue in nCRT‑well group patients than in nCRT‑poor group patients. Illumina HiSeq 4000 sequencing identified 2925 hypo‑differentially hydroxymethylated region (DhMRs) and 292 hyper‑DhMRs in promoter between nCRT‑well and nCRT‑poor patients. Biological processes associated with hyper‑DhMRs included ‘snRNA processing’, ‘hormone‑mediated signaling pathway’ and ‘cellular response’. Metabolic processes were associated with hypo‑DhMRs. These data may explain the functional response to nCRT in patients with abnormal promoter of methylation gene‑associated mRNA expression. The present results implied that hyper‑DhMRs and hypo‑DhMRs affect molecular pathways, such as hippo and Notch signaling pathways, highlighting epigenetic modifications associated with clinical response to nCRT in patients with esophageal cancer.